A phase II neoadjuvant trial of sequential nab-paclitaxel followed by dose dense epirubicine/cyclophosphamide (ddEC) in operable breast cancer
Phase 2
Recruiting
- Conditions
- breast cancer
- Registration Number
- JPRN-UMIN000041509
- Lead Sponsor
- Breast Surgery, Yokkaichi Municipal Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)Known hypersensitivity to human serum alb umin 2)Concurrent, serious or uncontrolled infect ions 3)Inadequately controlled or serious history of cardiac disease 4)Confirmed symptomatic brain metastasis 5)Current pregnancy and lactation, or possib ility of pregnancy 6)Known drug allergy to any of study drugs 7)Assessment by investigator that subject un able to comply with protocol
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pathological complete response (pCR) in breast and axillary lymph node
- Secondary Outcome Measures
Name Time Method Adverse events with nab-paclitaxel and ddEC therapy